These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 29937354)
1. Apoptotic Cell-Derived Extracellular Vesicles Promote Malignancy of Glioblastoma Via Intercellular Transfer of Splicing Factors. Pavlyukov MS; Yu H; Bastola S; Minata M; Shender VO; Lee Y; Zhang S; Wang J; Komarova S; Wang J; Yamaguchi S; Alsheikh HA; Shi J; Chen D; Mohyeldin A; Kim SH; Shin YJ; Anufrieva K; Evtushenko EG; Antipova NV; Arapidi GP; Govorun V; Pestov NB; Shakhparonov MI; Lee LJ; Nam DH; Nakano I Cancer Cell; 2018 Jul; 34(1):119-135.e10. PubMed ID: 29937354 [TBL] [Abstract][Full Text] [Related]
2. Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma. Correa BR; de Araujo PR; Qiao M; Burns SC; Chen C; Schlegel R; Agarwal S; Galante PA; Penalva LO Genome Biol; 2016 Jun; 17(1):125. PubMed ID: 27287018 [TBL] [Abstract][Full Text] [Related]
3. Extracellular vesicles in the biology of brain tumour stem cells--Implications for inter-cellular communication, therapy and biomarker development. Nakano I; Garnier D; Minata M; Rak J Semin Cell Dev Biol; 2015 Apr; 40():17-26. PubMed ID: 25721810 [TBL] [Abstract][Full Text] [Related]
4. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Gallo-Oller G; Vollmann-Zwerenz A; Meléndez B; Rey JA; Hau P; Dotor J; Castresana JS Cancer Lett; 2016 Oct; 381(1):67-75. PubMed ID: 27473823 [TBL] [Abstract][Full Text] [Related]
5. Identification of WISP1 as a novel oncogene in glioblastoma. Jing D; Zhang Q; Yu H; Zhao Y; Shen L Int J Oncol; 2017 Oct; 51(4):1261-1270. PubMed ID: 28902353 [TBL] [Abstract][Full Text] [Related]
6. Metformin treatment reduces temozolomide resistance of glioblastoma cells. Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Xi Z; Wang P; Xue Y; Shang C; Liu X; Ma J; Li Z; Li Z; Bao M; Liu Y Oncotarget; 2017 Apr; 8(15):24949-24963. PubMed ID: 28212562 [TBL] [Abstract][Full Text] [Related]
8. Extracellular Vesicles in Glioblastoma Tumor Microenvironment. Yekula A; Yekula A; Muralidharan K; Kang K; Carter BS; Balaj L Front Immunol; 2019; 10():3137. PubMed ID: 32038644 [TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2. Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898 [TBL] [Abstract][Full Text] [Related]
10. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p. Yin J; Ge X; Shi Z; Yu C; Lu C; Wei Y; Zeng A; Wang X; Yan W; Zhang J; You Y Theranostics; 2021; 11(4):1763-1779. PubMed ID: 33408780 [No Abstract] [Full Text] [Related]
11. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285 [TBL] [Abstract][Full Text] [Related]